BLS Pharmaceuticals LimitedASX: BLS

BLS Quarterly Activities Report September 2026 Revised

· Issued by BLS Pharmaceuticals Limited via ASX

Filed with ASX · · 11 pages · English

Summary by 6ix AI

The report indicates a significant increase in revenue driven by higher manufacturing volumes and ongoing international supply agreements, particularly in Germany. The company also reaffirmed its guidance for the financial year, expecting substantial revenue growth supported by increased manufacturing capacity and new customer onboarding. Additionally, BLS is expanding its international operations, including the development of a GMP facility in Scotland to enhance its manufacturing capabilities.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Suite 506, Level 5 50 Clarence Street, Sydney NSW 2000, Australia hello@breathelifesciences.com +61 2 9078 8180BLS Pharmaceuticals Ltd | ASX:BLS | www.blspharma.com 1 15 October 2026 Quarterly Activities Report Period Ending 30 September 2026 Record $26.7 million Q1 revenue provides strong start to...

BLS Pharmaceuticals Limited on 6ix

Story so far

Earlier from BLS Pharmaceuticals

All BLS Pharmaceuticals news releases